Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15450547 | 0.85 | TET2 (0.39) | TET2RECQLALDH1A1LMNATSHR | |
| SCHEMBL23248627 | 0.82 | CTH (0.35) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL25586113 | 0.81 | TET2 (0.37) | TET2RECQLALDH1A1LMNATSHR | |
| SCHEMBL3267023 | 0.78 | TET2 (0.43) | TET2RECQLALDH1A1LMNATSHR | |
| SCHEMBL21129653 | 0.73 | TET2 (0.46) | TET2RECQLALDH1A1LMNATSHR | |
| SCHEMBL757885 | 0.72 | TET2 (0.50) | TET2RECQLALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL344744 | 0.70 | TET2 (0.48) | TET2RECQLALDH1A1LMNATSHR | |
| SCHEMBL16532927 | 0.69 | TET2 (0.46) | TET2RECQLALDH1A1LMNATSHR | |
| SCHEMBL17125032 | 0.67 | TET2 (0.45) | TET2RECQLALDH1A1LMNATSHR | |
| SCHEMBL15621164 | 0.67 | TET2 (0.45) | TET2RECQLALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742139-B2 | No-carrier-added nucleophilic [F-18] fluorination of aromatic compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-03 | — | — | US | disclosed |
| US-8637560-B2 | Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637560-B2 | Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-01-28 | — | — | US | disclosed |
| US-20100286091-A1 | IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2010-11-11 | — | — | US | disclosed |
| US-20100286091-A1 | IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2010-11-11 | — | — | US | disclosed |
| WO-2009011910-A2 | IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERICES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286091-A1 | IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT | UBQLN2, UBQLN1, USP47 | TET2 3398/4885RECQL 800/4885ALDH1A1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.